참고문헌 (35)

1. Maurer M, Weller K, Bindslev-Jensen C, Gimenez-Arnau A, Bousquet PJ, Bousquet J, et al. Unmet clinical needs in chronic spontaneous urticaria. A GA 2 LEN task force report. Allergy 2011;66:317-30. 

2. Lee N, Lee JD, Lee HY, Kang DR, Ye YM. Epidemiology of Chronic Urticaria in Korea Using the Korean Health Insurance Database, 2010-2014. Allergy Asthma Immunol Res. 2017;9(5):438-45. 

   상세보기

3. Gaig P, Olona M, Munoz Lejarazu D, Caballero MT, Dominguez FJ, Echechipia S, et al. Epidemiology of urticaria in Spain. J Investig Allergol Clin Immunol 2004;14:214-20. 

   상세보기

4. Kozel MM, Mekkes JR, Bossuyt PM, Bos JD. Natural course of physical and chronic urticaria and angioedema in 220 patients. J Am Acad Dermatol 2001;45:387-91. 

   상세보기

5. Dias GA, Pires GV, Valle SO, Dortas SD Junior, Levy S, Franca AT, et al. Impact of chronic urticaria on the quality of life of patients followed up at a university hospital. An Bras Dermatol. 2016;91(6):754-9. 

6. Hiragun M, Hiragun T, Mihara S, Akita T, Tanaka J, Hide M. Prognosis of chronic spontaneous urticaria in 117 patients not controlled by a standard dose of antihistamine. Allergy. 2013;68(2):229-35. 

   상세보기

7. Van der Valk PG, Moret G, Kiemeney LA. The natural history of chronic urticaria and angioedema in patients visiting a tertiary referral centre. Br J Dermatol. 2002;146:110-3. 

   상세보기

8. Kaplan AP, Greaves M. Pathogenesis of chronic urticaria. Clin Exp Allergy. 2009; 39(6):777-87. 

   상세보기

9. Maurer M, Abuzakouk M, Berard F, Canonica W, Oude Elberink H, Gimenez-Arnau A, et al. The burden of chronic spontaneous urticaria is substantial: Real-world evidence from ASSURE-CSU. Allergy. 2017;72(12):2005-16. 

   상세보기

10. Zuberbier T, Aberer W, Asero R, et al. The EAACI/GA 2 LEN/EDF/WAO guideline for the definition, classification, diagnosis and management of urticaria. Allergy. 2018;73 (7):1393-414. 

    상세보기

11. Mlynek A, Zalewska-Janowska A, Martus P, Staubach P, Zuberbier T, Maurer M. How to assess disease activity in patients with chronic urticaria?. Allergy. 2008;63(6): 777-80. 

    상세보기

12. Black N. Patient reported outcome measures could help transform healthcare. BMJ. 2013;346:1-5. 

13. Choi JS, Park YS, Kim JH, Park CS. International Trends on Patient-Reported Outcome Measures for Improving Care Quality and Its Implication for South Korea: Focus on OECD PaRIS. Qual Improv Health Care. 2019;25(1):11-28. 

14. Bae Y, Kang SH, Park JO, Park GH, Choi JH. Serum transglutaminase 2 activity as a potential biomarker of disease severity and response to omalizumab in chronic spontaneous urticaria. Allergol Int. 2020;69(2):304-6. 

    상세보기

15. Baiardini I, Braido F, Bindslev-Jensen C, Bousquet PJ, Brzoza Z, Canonica GW et al. Recommendations for assessing patient-reported outcomes and health related quality of life in patients with urticaria: a GA2LEN taskforce position paper. Allergy. 2011;66:840-4. 

    상세보기

16. Baiardini I, Canonica GW, La Grutta S, Braido F. Clinically significant differences in patient-reported outcomes evaluations in chronic spontaneous urticaria. Curr Opin Allergy Clin Immunol. 2020;20(3):261-7. 

17. Hopkinson K. The role of patient-reported outcomes in the management of chronic spontaneous urticaria. Br J Nurs. 2019; 28(3):144-50. 

    상세보기

18. Moestrup K, Ghazanfar MN, Thomsen SF. Patient-reported outcomes (PROs) in chronic urticaria. Int J Dermatol. 2017;56(12): 1342-8. 

    상세보기

19. Park SY, Kang MS, Kim MH, Kwak JY, Choi IH. A Review of Assessment Tools in Traditional Medicine on the High Frequent Skin Diseases. J Korean Med Ophthalmol Otolaryngol Dermatol. 2018;31(4):31-41. 

    원문보기 상세보기

20. Patruno C, Napolitano M, Ferrucci S, Brambilla L, Hansel K, Corazza M et al. Four-week Urticaria Activity Score-7 as a Useful Patient-reported Outcome to Assess Chronic Spontaneous Urticaria: A Multicentre Study Evaluation of Adherence and Patients' Perspective. Acta Derm Venereol. 2019;99(10):903-4. 

    상세보기

21. Weller K, Church MK, Metz M, Hawro T, Ohanyan T, Staubach P et al. The response to treatment in chronic spontaneous urticaria depends on how it is measured. J Allergy Clin Immunol Pract. 2019;7(6): 2055-6. 

22. Weller K, Groffik A, Church MK, Hawro T, Krause K, Metz M, et al. Development and validation of the Urticaria Control Test: a patient-reported outcome instrument for assessing urticaria control. J Allergy Clin Immunol. 2014;133(5):1365-72. 

    상세보기

23. Lee JH, Bae YJ, Lee SH, Kim SC, Lee HY, Ban GY, et al. Adaptation and Validation of the Korean Version of the Urticaria Control Test and Its Correlation With Salivary Cortisone. Allergy Asthma Immunol Res. 2019;11(1):55-67. 

24. Patruno C, Napolitano M, Ferrucci S, Brambilla L, Hansel K, Corazza M, et al. Four-week Urticaria Activity Score-7 as a Useful Patient-reported Outcome to Assess Chronic Spontaneous Urticaria: A Multicentre Study Evaluation of Adherence and Patients' Perspective. Acta Derm Venereol. 2019;99(10):903-4. 

    상세보기

25. Huber LR, Broel EC, Mitchelides AN, Dmochowski J, Dulin M, Scholes D. Comparison of prospective daily diaries and retrospective recall to measure oral contraceptive adherence. Contraception. 2013;88(4):492-7. 

    상세보기

26. Gimenez-Arnau A, Bartra J, Ferrer M, Jauregui I, Borbujo J, Figueras I, et al. A Specialized Therapeutic Approach to Chronic Urticaria Patient's Refractory to H1-Antihistamines Improves the Burden of the Disease. The Spanish AWARE Experience. 2022;32(3):1-27. 

27. Dekkers C, Alizadeh Aghdam M, de Graaf M, Knulst AC, Meijer Y, van den Reek JMPA, et al. Safety and effectiveness of omalizumab for the treatment of chronic urticaria in pediatric patients. Pediatr Allergy Immunol. 2021;00:1-7. 

28. Oliver ET, Chichester K, Devine K, Sterba PM, Wegner C, Vonakis BM, et al. Effects of an Oral CRTh2 Antagonist (AZD1981) on Eosinophil Activity and Symptoms in Chronic Spontaneous Urticaria. Int Arch Allergy Immunol. 2019;179(1):21-30. 

    상세보기

29. Ertas R, Ozyurt K, Atasoy M, Hawro T, Maurer M. The clinical response to omalizumab in chronic spontaneous urticaria patients is linked to and predicted by IgE levels and their change. Allergy. 2018;73(3):705-12. 

    상세보기

30. Zhang L, Qi R, Yang Y, Gao X, Chen H, Xiao T. Serum miR-125a-5p and CCL17 Upregulated in Chronic Spontaneous Urticaria and Correlated with Treatment Response. Acta Derm Venereol. 2019;99 (6):571-8. 

    상세보기

31. Maurer M, Mathias SD, Crosby RD, Rajput Y, Zazzali JL. Validity and responsiveness of the Urticaria Activity and Impact Measure: A new patient-reported tool. Ann Allergy Asthma Immunol. 2018;120(6):641-7. 

    상세보기

32. Kaliyadan F, Ashique KT. Use of Mobile Applications in Dermatology. Indian J Dermatol. 2020;65(5):371-6. 

    상세보기

33. Seo JS, Kim YE, Kim AN, Kim IT, Son YH, Jang HC. Study on Compliance of Personal Health Record Application in Patients with Atopic Dermatitis. J Society of Preventive Korean Medicine. 2020;24(2):71-82. 

34. Rijsbergen M, Niemeyer-van der Kolk T, Rijneveld R, Pinckaers JHFM, Meshcheriakov I, Bouwes Bavinck JN, et al. Mobile e-diary application facilitates the monitoring of patient-reported outcomes and a high treatment adherence for clinical trials in dermatology. J Eur Acad Dermatol Venereol. 2020;34(3):633-9. 

    상세보기

35. Hide M, Igarashi A, Yagami A, Chinuki Y, Inomata N, Fukunaga A, et al. Efficacy and safety of omalizumab for the treatment of refractory chronic spontaneous urticaria in Japanese patients: Subgroup analysis of the phase 3 POLARIS study. Allergol Int. 2018;67(2):243-52. 

    상세보기

저자의 다른 논문 :

최인화 (58) 강민서 (6)